Equine Healthcare Market by Product Type, Disease, and Distribution Channel : Opportunity Analysis and Industry Forecast, 2020-2030

Description

List of Tables

Equine health is an important aspect of a horse's quality of life. Maintaining good health in racehorses is vital as proper management can reduce the incidence of many disease conditions. As horses interact with its environment, it relies on health concerns to maintain proper performance and stability of horses. Understanding the horse's health can help to promote its overall well-being. The healthcare of horses includes routine veterinary care for vaccinations, parasite control, and dental care; grooming and hoof care; and protection.

The global equine healthcare devices market was valued at $1,206.70 million in 2020, and is projected to reach $2,328.90 million by 2030, registering a CAGR of 6.80% from 2021 to 2030, owing to rise in prevalence of equine diseases, increase in equine population, increase in animal health expenditure, rise in demand for use of horses for various purposes, increase in advancements of equine healthcare products, and growing awareness among the population about the importance and benefits of horses healthcare. However, decline in equine population is expected to hamper the market growth.

The global equine healthcare market is segmented into product type, disease, and distribution channel. Based on product type, the market is categorized into drug, vaccines, and medicated feed additives. Furthermore, drugs are classified into anti-infectives, anti-inflammatory, parasiticides, and others. Vaccines are classified into inactivated, live attenuated, recombinant, and others. Based on disease, the market is divided into influenza, tetanus, equine herpes virus, and others (equine encephalomyelitis, west nile virus, equine rabies, and potomac horse fever). On the basis of distribution channel, it is bifurcated into veterinary hospitals and clinics and retail pharmacies and drug stores. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the hemodialysis and peritoneal dialysis market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Product Type

Drug
Anti-Infectives
Anti-Inflammatory
Parasiticides
Others
Vaccines
Inactivated
Live Attenuated
Recombinant
Others
Medicated Feed Additives

By Disease

Influenza
Tetanus
Equine Herpes Virus
Others

By Distribution Channel

Veterinary Hospitals and Clinics
Retail Pharmacies and Drug Stores

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Thermo Fisher Scientific (Affymetrix)
Elanco Animal Health (Bayer Animal Health)
Boehringer Ingelheim
Ceva Sante Animale
Land o Lakes (Purina Mills LLC)
EQUINE PRODUCTS UK LTD
Merck & Co. (Merck Animal Health)
Sanofi (Merial)
Vetoquinol S.A.
Zoetis

Product Code: LI_18387 / A00294

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
- 1.3.1.List of key players profiled in the report
1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
- 3.2.2.Top winning strategies
3.3.Porter's five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
- 3.5.1.Drivers
  - 3.5.1.1.Increase in prevalence of equine diseases
  - 3.5.1.2.Rise in animal health expenditure
- 3.5.2.Restraint
  - 3.5.2.1.Decline in global equine population
- 3.5.3.Opportunities
  - 3.5.3.1.Rise in demand for pet insurance
- 3.5.4.Impact analysis
3.6.COVID-19 Impact Analysis on Equine healthcare Market

CHAPTER 4:EQUINE HEALTHCARE MARKET, BY PRODUCT

4.1.Overview
- 4.1.1.Market size and forecast
4.2.Drug
- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by region
- 4.2.3.Market analysis, by country
- 4.2.4.Anti-infectives Drugs
  - 4.2.4.1.Market size and forecast
- 4.2.5.Anti-Inflammatory Drugs
  - 4.2.5.1.Market size and forecast
- 4.2.6.Parasiticide Drugs
  - 4.2.6.1.Market size and forecast
- 4.2.7.Other Drugs
  - 4.2.7.1.Market size and forecast
4.3.Vaccines
- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast
- 4.3.3.Market analysis, by country
- 4.3.4.Inactivated Vaccines
  - 4.3.4.1.Market size and forecast
- 4.3.5.Live Attenuated Vaccine
  - 4.3.5.1.Market size and forecast
- 4.3.6.Recombinant Vaccine
  - 4.3.6.1.Market size and forecast
- 4.3.7.Other vaccines
  - 4.3.7.1.Market size and forecast
4.4.Medicated feed additives
- 4.4.1.Key market trends, growth factors, and opportunities
- 4.4.2.Market size and forecast
- 4.4.3.Market analysis, by country

CHAPTER 5:EQUINE HEALTHCARE MARKET, BY DISEASES

5.1.Overview
- 5.1.1.Market size and forecast
5.2.Influenza
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
5.3.Tetanus
- 5.3.1.Market size and forecast, by region
- 5.3.2.Market analysis, by country
5.4.Equine Herpes Virus
- 5.4.1.Market size and forecast, by region
- 5.4.2.Market analysis, by country
5.5.Other diseases
- 5.5.1.Market size and forecast, by region
- 5.5.2.Market analysis, by country

CHAPTER 6:EQUINE HEALTHCARE MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview
- 6.1.1.Market size and forecast
6.2.Veterinary Hospitals and Clinics
- 6.2.1.Market size and forecast, by region
- 6.2.2.Market analysis, by country
6.3.Retail pharmacies and Drug Stores
- 6.3.1.Market size and forecast, by region
- 6.3.2.Market analysis, by country

CHAPTER 7:EQUINE HEALTHCARE MARKET, BY REGION

7.1.Overview
- 7.1.1.Market size and forecast
7.2.North America
- 7.2.1.Key market trends, growth factors, and opportunities
  - 7.2.3.1.U.S.
  - 7.2.3.1.1.U.S. Equine Healthcare market, by product type
  - 7.2.3.1.2.U.S. Equine Healthcare market, by diseases
  - 7.2.3.1.3.U.S. Equine Healthcare market, by distribution channel
  - 7.2.3.2.Canada
  - 7.2.3.2.1.Canada Equine Healthcare market, by product type
  - 7.2.3.2.2.Canada Equine Healthcare market, by diseases
  - 7.2.3.2.3.Canada Equine Healthcare market, by distribution channel
  - 7.2.3.3.Mexico
  - 7.2.3.3.1.Mexico Equine Healthcare market, by product type
  - 7.2.3.3.2.Mexico Equine Healthcare market, by diseases
  - 7.2.3.3.3.Mexico Equine Healthcare market, by distribution channel
- 7.2.4.North America market size and forecast, by product type
- 7.2.5.North America market size and forecast, by diseases
- 7.2.6.North America market size and forecast, by distribution channel
7.3.Europe
- 7.3.1.Key market trends, growth factors, and opportunities
- 7.3.2.Market size and forecast, by country
  - 7.3.2.1.Germany
  - 7.3.2.1.1.Germany Equine Healthcare market, by product type
  - 7.3.2.1.2.Germany Equine Healthcare market, by diseases
  - 7.3.2.1.3.Germany Equine Healthcare market, by distribution channel
  - 7.3.2.2.France
  - 7.3.2.2.1.France Equine Healthcare market, by product type
  - 7.3.2.2.2.France Equine Healthcare market, by diseases
  - 7.3.2.2.3.France Equine Healthcare market, by distribution channel
  - 7.3.2.3.UK
  - 7.3.2.3.1.UK Equine Healthcare market, by product type
  - 7.3.2.3.2.UK Equine Healthcare market, by diseases
  - 7.3.2.3.3.UK Equine Healthcare market, by distribution channel
  - 7.3.2.4.Italy
  - 7.3.2.4.1.Italy Equine Healthcare market, by product type
  - 7.3.2.4.2.Italy Equine Healthcare market, by diseases
  - 7.3.2.4.3.Italy Equine Healthcare market, by distribution channel
  - 7.3.2.5.Spain
  - 7.3.2.5.1.Spain Equine Healthcare market, by product type
  - 7.3.2.5.2.Spain Equine Healthcare market, by diseases
  - 7.3.2.5.3.Spain Equine Healthcare market, by distribution channel
  - 7.3.2.6.Rest of Europe
  - 7.3.2.6.1.Rest of Europe Equine Healthcare market, by product type
  - 7.3.2.6.2.Rest of Europe Equine Healthcare market, by diseases
  - 7.3.2.6.3.Rest of Europe Equine Healthcare market, by distribution channel
- 7.3.3.Europe market size and forecast, by product type
- 7.3.4.Europe market size and forecast, by diseases
- 7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
- 7.4.1.Key market trends, growth factors, and opportunities
- 7.4.2.Market size and forecast, by country
  - 7.4.2.1.Japan
  - 7.4.2.1.1.Japan Equine Healthcare market, by product type
  - 7.4.2.1.2.Japan Equine Healthcare market, by diseases
  - 7.4.2.1.3.Japan Equine Healthcare market, by distribution channel
  - 7.4.2.2.China
  - 7.4.2.2.1.China Equine Healthcare market, by product type
  - 7.4.2.2.2.China Equine Healthcare market, by diseases
  - 7.4.2.2.3.China Equine Healthcare market, by distribution channel
  - 7.4.2.3.Australia
  - 7.4.2.3.1.Australia Equine Healthcare market, by product type
  - 7.4.2.3.2.Australia Equine Healthcare market, by diseases
  - 7.4.2.3.3.Australia Equine Healthcare market, by distribution channel
  - 7.4.2.4.India
  - 7.4.2.4.1.India Equine Healthcare market, by product type
  - 7.4.2.4.2.India Equine Healthcare market, by diseases
  - 7.4.2.4.3.India Equine Healthcare market, by distribution channel
  - 7.4.2.5.South Korea
  - 7.4.2.5.1.South Korea Equine Healthcare market, by product type
  - 7.4.2.5.2.South Korea Equine Healthcare market, by diseases
  - 7.4.2.5.3.South Korea Equine Healthcare market, by distribution channel
  - 7.4.2.6.Rest of Asia-Pacific
  - 7.4.2.6.1.Rest of Asia-Pacific Equine Healthcare market, by product type
  - 7.4.2.6.2.Rest of Asia-Pacific Equine Healthcare market, by diseases
  - 7.4.2.6.3.Rest of Asia-Pacific Equine Healthcare market, by distribution channel
- 7.4.3.Asia-Pacific market size and forecast, by product type
- 7.4.4.Asia-Pacific market size and forecast, by diseases
- 7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
- 7.5.1.Key market trends, growth factors, and opportunities
- 7.5.2.Market size and forecast, by country
  - 7.5.2.1.Brazil
  - 7.5.2.1.1.Brazil Equine Healthcare market, by product type
  - 7.5.2.1.2.Brazil Equine Healthcare market, by diseases
  - 7.5.2.1.3.Brazil Equine Healthcare market, by distribution channel
  - 7.5.2.2.Saudi Arabia
  - 7.5.2.2.1.Saudi Arabia Equine Healthcare market, by product type
  - 7.5.2.2.2.Saudi Arabia Equine Healthcare market, by diseases
  - 7.5.2.2.3.Saudi Arabia Equine Healthcare market, by distribution channel
  - 7.5.2.3.South Africa
  - 7.5.2.3.1.South Africa Equine Healthcare market, by product type
  - 7.5.2.3.2.South Africa Equine Healthcare market, by diseases
  - 7.5.2.3.3.South Africa Equine Healthcare market, by distribution channel
  - 7.5.2.4.Rest of LAMEA
  - 7.5.2.4.1.Rest of LAMEA Equine Healthcare market, by product type
  - 7.5.2.4.2.Rest of LAMEA Equine Healthcare market, by diseases
  - 7.5.2.4.3.Rest of LAMEA Equine Healthcare market, by distribution channel
- 7.5.3.LAMEA market size and forecast, by product type
- 7.5.4.LAMEA market size and forecast, by diseases
- 7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.Boehringer Ingelheim International GmbH
- 8.1.1.Company overview
- 8.1.2.Company snapshot
- 8.1.3.Operating business segments
- 8.1.4.Product portfolio
- 8.1.5.Key strategic moves and developments
8.2.Ceva Sante Animale
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Product portfolio
8.3.Elanco Animal Health Inc. (Bayer Animal Health)
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product portfolio
- 8.3.5.Business performance
- 8.3.6.Key strategic moves and developments
8.4.Equine Products UK LTD
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product portfolio
- 8.4.5.Key strategic moves and developments
8.5.Land O'Lakes, Inc. (Purina Mills, LLC)
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Product portfolio
8.6.MERCK & CO., INC.(Merck Animal Health)
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Product portfolio
- 8.6.5.Business performance
8.7.Sanofi S.A. (Merial)
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product portfolio
- 8.7.5.Business performance
8.8.Thermo Fisher Scientific Inc. (Affymetrix Inc.)
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.8.5.Business performance
8.9.Vetoquinol S.A.
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
- 8.9.5.Business performance
8.10.Zoetis Inc.
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance
- 8.10.6.Key strategic moves and developments